The food and drug administration's drug safety oversight board: An evolving paradigm for clinical input on drug safety topics

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 2, 2010, Pages 269-274

  Grandinetti, C A ^a   Osborne, S F ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG EFFECT; DRUG SAFETY; FEEDBACK SYSTEM; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMMUNICATION; HUMANS; LEGISLATION, DRUG; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954887903     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.82     Document Type: Review

References (21)

1. Temple, R. Policy developments in regulatory approval. Stat. Med. 21, 2939-2948 (2002).
2. Masters, B. & Kaufman, M. Painful withdrawal for makers of Vioxx. The Washington Post, 18 October 2004 and 18 August 2009
3. Huang, S.M. et al. New era in drug interaction evaluation: Us Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 48, 662-670 (2008).
4. Henney, J.E. Withdrawal of troglitazone and cisapride. JAMA 283, 2228 (2000).
5. Us Food and Drug Administration. FDA Public Health Advisory: Reports of Valvular Heart Disease in Patients Receiving Concomitant Fenfuramine and Phentermine (1997).
6. Huang, S.M. et al. Evaluation of drugs in women: regulatory perspective. In Principles of Gender-Specifc Medicine (ed. Legato, M.J.) 848-859 Elsevier Academic Press, Amsterdam, the Netherlands, 2004).
7. Us Food and Drug Administration. Prescription Drug User Fee Act Legislation and Background. Accessed 20 May 2009.
8. Leavitt: reforms will improve oversight and openness at FDA. FDA Consum. 39, 37 (2005)
9. Committee on the Assessment of the Us Drug safety system. The Future of Drug Safety: Promoting and Protecting the Health of the Public. National Academies Press, Washington, DC, (2007).
10. 110th Congress. Food and Drug Administration Amendment Act of 2007. Public Law 110-85, 27 september 2007.
11. Psaty, B.M. & Korn, D. Congress responds to the IOM drug safety report-in full. JAMA 298, 2185-2187 (2007).
12. Us Food and Drug Administration. guidance for Industry: Format and Content of Proposed Risk Evaluation and Mitigation strategies (REMs), REMs Assessments and Proposed REMs Modifcation (Draft guidance) (2009)
13. Seligman, P.J. & Osborne, S.F. Perspectives on early communication of drug risks to the public. Clin. Pharmacol. Ther. 85, 335-339 (2009).
14. Us Food and Drug Administration. Food and Drug Administration Information for Healthcare Professionals. Accessed 7 January 2010.
15. Us Food and Drug Administration. Food and Drug Administration Public Health Advisories. Accessed 7 January 2010. Us Food and Drug Administration. Food and Drug Administration Early Communication About an Ongoing safety Review. Accessed 7 January 2010.
16. Us Food and Drug Administration. FDA's strategic Plan for Risk Communication (2009). Pub.L.92-463. Federal Advisory Committee Act (FACA); Public Law 92-463. Accessed 6 October 2009.
17. Us Food and Drug Administration. FDA's safe Use Initiative: Collaborating to Reduce Preventable Harm From Medications (2009).
18. Perrin, J.M., Friedman, R.A. & Knilans, T.K.; Black Box Working group; section on Cardiology and Cardiac surgery. Cardiovascular monitoring and stimulant drugs for attention-defcit/hyperactivity disorder. Pediatrics 122, 451-453 (2008).
19. Vetter, V.L. et al.; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention defcit/hyperactivity disorder [corrected]: a scientifc statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117, 2407-2423 (2008).
20. Gould, M.S. et al. sudden death and use of stimulant medications in youths. Am. J. Psychiatry 166, 992-1001 (2009).
21. Us Food and Drug Administration. Communication About an Ongoing safety Review of stimulant Medications Used in Children with Attention-Defcit/ Hyperactivity Disorder (ADHD) (2009). Accessed 4 January 2010.